Cardiovascular Drugs Practice Questions

Q: Which antihypertensive drug is absolutely contraindicated in pregnancy?

Enalapril. **Explanation:** **Enalapril (Option A)** is an ACE inhibitor and is **absolutely contraindicated** in pregnancy, particularly during the second and third trimesters. ACE inhibitors and Angiotensin Receptor Blockers (ARBs) interfere with the fetal renin-angiotensin system, which is crucial for renal development. Their use leads to **fetal renal dysgenesis**, which causes oligohydramnios. This lack of amniotic fluid results in the "ACE inhibitor fetopathy" triad: pulmonary hypoplasia, limb contractures, and calvarial (skull) hypoplasia. **Analysis of Incorrect Options:** * **Diazoxide (Option B):** While rarely used today due to the risk of sudden maternal hypotension and fetal hyperglycemia, it is not "absolutely contraindicated" in the same category as ACE inhibitors. * **Atenolol (Option C):** Though generally avoided in pregnancy because it is associated with **fetal growth restriction (IUGR)** and placental smallness, it is not teratogenic or absolutely contraindicated if no other options exist. * **Nifedipine (Option D):** A Calcium Channel Blocker (CCB) that is considered **safe and first-line** for the management of chronic hypertension and pre-eclampsia in pregnancy. **High-Yield Clinical Pearls for NEET-PG:** * **Drugs of Choice (DOC):** Labetalol (overall DOC), Methyldopa (safest long-term), and Nifedipine. * **Acute Hypertensive Crisis:** IV Labetalol or IV Hydralazine. * **Teratogenic triad of ACE inhibitors:** Renal failure, Oligohydramnios, and Hypocalvaria. * **Diuretics:** Generally avoided in pregnancy as they prevent the physiological expansion of plasma volume.

Q: Captopril can cause all of the following except:

Decrease in K+ concentration. **Explanation:** **Captopril** is an ACE (Angiotensin-Converting Enzyme) inhibitor. To understand its side effects, one must look at the Renin-Angiotensin-Aldosterone System (RAAS) blockade. **1. Why "Decrease in K+ concentration" is the correct answer:** ACE inhibitors block the conversion of Angiotensin I to Angiotensin II. Since Angiotensin II normally stimulates the adrenal cortex to release **aldosterone**, its inhibition leads to a decrease in aldosterone levels. Aldosterone is responsible for sodium reabsorption and potassium excretion in the distal tubule. Therefore, a decrease in aldosterone results in **potassium retention (Hyperkalemia)**, not a decrease in K+ concentration. **2. Analysis of incorrect options:** * **Decrease in afterload:** Angiotensin II is a potent vasoconstrictor. By blocking its production, ACE inhibitors cause systemic vasodilation, which directly reduces Total Peripheral Resistance (TPR) and afterload. * **Proteinuria:** While ACE inhibitors are generally nephroprotective in diabetics, Captopril (specifically due to its sulfhydryl group) has been associated with membranous glomerulopathy and proteinuria, especially at high doses. * **Blood dyscrasia:** Captopril can rarely cause neutropenia or agranulocytosis, particularly in patients with renal impairment or collagen vascular diseases. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for ACEI side effects (CAPTOPRIL):** **C**ough (due to Bradykinin), **A**ngioedema, **P**roteinuria/ **P**otassium excess, **T**aste changes (dysgeusia), **O**rthostatic hypotension, **P**regnancy contraindicated (Teratogenic), **R**enal artery stenosis (contraindicated), **I**ncreased renin, **L**eukopenia. * **First-dose hypotension** is a common phenomenon with ACE inhibitors. * Captopril is unique among ACE inhibitors because it contains a **sulfhydryl group**, which is linked to the higher incidence of skin rashes and taste disturbances.

Q: Which of the following statements is NOT true about nesiritide?

It has significant oral absorption.. ### Explanation **Nesiritide** is a recombinant form of human **B-type Natriuretic Peptide (BNP)**. Understanding its pharmacokinetic profile is crucial for NEET-PG. **Why Option C is the correct answer (The False Statement):** Nesiritide is a **polypeptide**. Like insulin or other protein-based drugs, it would be rapidly degraded by proteolytic enzymes in the gastrointestinal tract if taken orally. Therefore, it has **zero oral bioavailability** and must be administered exclusively via the **intravenous (IV)** route. **Analysis of Other Options:** * **Option A:** Nesiritide is indeed a recombinant B-type (Brain) Natriuretic Peptide analogue. It works by increasing intracellular cGMP, leading to smooth muscle relaxation. * **Option B:** Its primary clinical indication is **acutely decompensated heart failure (ADHF)** with dyspnea at rest. It provides "balanced" vasodilation (reducing both preload via venodilation and afterload via arteriodilation) and promotes natriuresis. * **Option D:** It has a very **short half-life** (approximately 18–20 minutes), necessitating administration as an IV bolus followed by a continuous infusion. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Binds to particulate guanylate cyclase receptor (NPR-A), increasing **cGMP**. * **Effects:** Vasodilation, natriuresis (sodium excretion), and diuresis; it lacks direct inotropic effects. * **Major Side Effect:** **Hypotension** is the most common dose-limiting adverse effect. Some studies also suggest a risk of worsening renal function. * **Mnemonic:** **N**esiritide = **N**atriuretic peptide for **N**ew (Acute) heart failure.

Q: Which of the following drugs can be used to treat hypertension induced by cyclosporine?

Enalapril. **Explanation:** The correct answer is **B. Enalapril**. **Mechanism and Rationale:** Cyclosporine, a calcineurin inhibitor used for immunosuppression, frequently causes hypertension as a side effect. The primary mechanism behind cyclosporine-induced hypertension is **systemic vasoconstriction** and **activation of the Renin-Angiotensin-Aldosterone System (RAAS)**. Cyclosporine increases the production of Endothelin-1 (a potent vasoconstrictor) and decreases the production of vasodilatory prostaglandins. Since RAAS activation is a hallmark of this condition, **ACE inhibitors (like Enalapril)** or Angiotensin Receptor Blockers (ARBs) are the preferred agents to counteract these effects and provide nephroprotection. **Analysis of Incorrect Options:** * **A. Clonidine & D. Methyldopa:** These are centrally acting alpha-2 agonists. While they lower blood pressure, they do not address the specific RAAS-mediated pathophysiology of cyclosporine-induced hypertension and are not first-line choices. * **C. Nifedipine:** While Calcium Channel Blockers (CCBs) are effective in treating cyclosporine-induced hypertension, **Dihydropyridines (like Nifedipine)** should be used with caution. More importantly, non-dihydropyridines (Verapamil/Diltiazem) are generally avoided because they inhibit Cytochrome P450 (CYP3A4), leading to toxic levels of cyclosporine. **Clinical Pearls for NEET-PG:** * **Drug of Choice:** ACE inhibitors/ARBs are preferred for cyclosporine-induced hypertension, especially in renal transplant patients, due to their ability to reduce efferent arteriolar resistance. * **Gingival Hyperplasia:** Both Cyclosporine and Nifedipine can cause gingival hyperplasia; using them together significantly increases this risk. * **Monitoring:** Always monitor serum potassium levels when using Enalapril with Cyclosporine, as both drugs can cause **hyperkalemia**.

Q: Iloprost in Pulmonary Arterial Hypertension is administered by which route?

Inhalation. **Explanation:** **Iloprost** is a synthetic analog of **Prostacyclin (PGI2)**. In the management of Pulmonary Arterial Hypertension (PAH), it acts as a potent pulmonary vasodilator and inhibitor of platelet aggregation. **Why Inhalation is the Correct Route:** The preferred route for Iloprost in PAH is **inhalation** via a nebulizer. This targeted delivery allows the drug to reach the pulmonary vasculature directly, causing localized vasodilation. This "selective" pulmonary effect minimizes systemic side effects (like systemic hypotension) and improves ventilation-perfusion (V/Q) matching by vasodilating only the well-ventilated areas of the lung. **Analysis of Incorrect Options:** * **Intravenous (A):** While other prostacyclins like **Epoprostenol** are primarily given via continuous IV infusion, Iloprost is specifically designed for inhalation to reduce the risks associated with permanent indwelling catheters (e.g., sepsis, thrombosis). * **Intramuscular (B):** This route is not used for prostacyclins due to unpredictable absorption and the risk of local pain/tissue irritation. * **Oral (C):** While an oral formulation of Iloprost exists in some countries, it is not the standard or most effective route for PAH compared to inhalation. **Selexipag** and **Beraprost** are the more common oral prostacyclin-pathway agents. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Increases cAMP in vascular smooth muscle cells leading to vasodilation. * **Half-life:** Iloprost has a very short half-life (approx. 20–30 mins), requiring frequent dosing (6–9 inhalations per day). * **Side Effects:** Common side effects include cough, flushing, headache, and jaw pain. * **Drug of Choice:** For PAH, **Bosentan** (Endothelin antagonist) or **Sildenafil** (PDE-5 inhibitor) are often first-line, while prostacyclins are added in advanced stages (WHO Class III/IV).

Q: What is the antihypertensive of choice for a hypertensive diabetic patient with proteinuria?

Enalaprilat. **Explanation:** **1. Why Enalaprilat is the Correct Answer:** In patients with diabetes mellitus and hypertension, **ACE inhibitors (ACEIs)** like Enalaprilat (the active metabolite of Enalapril) are the drugs of choice. The underlying medical concept is **Renoprotection**. ACEIs dilate the efferent arteriole more than the afferent arteriole in the kidney. This reduces intraglomerular capillary pressure, thereby decreasing **proteinuria** and slowing the progression of diabetic nephropathy. They also improve insulin sensitivity, making them metabolic-neutral or beneficial. **2. Why the Other Options are Incorrect:** * **Propranolol (Beta-blocker):** Generally avoided as a first-line agent in diabetics because it can mask the warning symptoms of hypoglycemia (tachycardia, tremors) and may worsen glycemic control by inhibiting insulin release. * **Clonidine (Alpha-2 agonist):** A centrally acting drug used primarily for resistant hypertension. It has no specific renoprotective benefits and is associated with side effects like sedation and dry mouth. * **Alpha-methyldopa:** This is the drug of choice for hypertension in **pregnancy**. It is not preferred for diabetic patients as it lacks the specific antiproteinuric effects of ACEIs. **3. NEET-PG High-Yield Pearls:** * **Drug of Choice (DOC):** ACEIs or ARBs (Angiotensin Receptor Blockers) are the DOC for hypertension with Diabetes, Chronic Kidney Disease (CKD), and Heart Failure. * **Side Effects of ACEIs:** Remember the mnemonic **CAPTOPRIL** (Cough, Angioedema, Proteinuria/Potassium excess, Taste changes, Orthostatic hypotension, Pregnancy contraindication, Renal artery stenosis contraindication, Increased renin, Leukopenia). * **Contraindication:** ACEIs/ARBs are strictly contraindicated in **bilateral renal artery stenosis** (can cause acute renal failure) and **pregnancy** (teratogenic).

Q: Renolazine is used in the management of which condition?

Angina. **Explanation:** **Ranolazine** is a novel anti-anginal drug used primarily in the management of **chronic stable angina**. **Why Angina is Correct:** The core mechanism of Ranolazine involves the **selective inhibition of the late inward sodium current ($I_{Na}$)** in myocardial cells. During ischemia, there is an excess influx of sodium through these channels, which leads to an overload of intracellular calcium (via the $Na^+/Ca^{2+}$ exchanger). High calcium levels cause wall stiffness and increased diastolic tension, further compromising coronary blood flow. By blocking the late $I_{Na}$, Ranolazine reduces calcium overload, improves myocardial relaxation (diastolic function), and enhances coronary perfusion without significantly affecting heart rate or blood pressure. **Why Other Options are Incorrect:** * **Hypertension:** Ranolazine has negligible effects on systemic blood pressure and is not indicated for hypertension. * **Tachycardia:** Unlike beta-blockers or calcium channel blockers, Ranolazine does not significantly reduce the heart rate. * **Arrhythmia:** While Ranolazine can cause a modest prolongation of the **QT interval** (by blocking $I_{Kr}$ channels), it is not used as a primary anti-arrhythmic agent. In fact, its effect on the QT interval requires cautious monitoring. **High-Yield Clinical Pearls for NEET-PG:** * **Metabolism:** It is metabolized by **CYP3A4**; therefore, it is contraindicated with potent inhibitors like ketoconazole or clarithromycin. * **Unique Feature:** It is a "p-FOX inhibitor" (partial fatty acid oxidation inhibitor), shifting myocardial metabolism from fatty acids to glucose, which requires less oxygen. * **Usage:** It is typically used as a **second-line** add-on therapy when symptoms are not controlled by first-line agents (Beta-blockers/CCBs). * **Side Effects:** Dizziness, headache, constipation, and QT prolongation.

Q: All of the following drugs cause arteriolar dilatation except?

Glyceryl trinitrate. The primary mechanism of action for vasodilators depends on whether they act on the arterial side, the venous side, or both. **Why Glyceryl Trinitrate (GTN) is the correct answer:** Glyceryl trinitrate (Nitroglycerin) is a **predominant venodilator** [1]. At therapeutic doses, it acts mainly on the capacitance vessels (veins), leading to peripheral pooling of blood, decreased venous return, and a reduction in **preload** [2]. While it can cause arteriolar dilatation at very high doses, its primary clinical effect and classification distinguish it from pure arteriolar dilators [2]. **Analysis of Incorrect Options:** * **Hydralazine:** A direct-acting **arteriolar dilator** [3]. It acts by increasing cGMP levels and interfering with calcium release from the sarcoplasmic reticulum in smooth muscle. It has minimal effect on veins [1], [3]. * **Diazoxide:** A potent **arteriolar dilator** that works by opening ATP-sensitive potassium channels ($K_{ATP}$), leading to hyperpolarization of smooth muscle cells [3]. It is used in hypertensive emergencies and insulinomas. * **Nifedipine:** A Calcium Channel Blocker (Dihydropyridine class) that specifically targets L-type calcium channels in the **arteriolar smooth muscle**, causing significant vasodilation and a reduction in afterload [3]. **NEET-PG High-Yield Pearls:** 1. **Pure Arteriolar Dilators:** Hydralazine, Minoxidil, Diazoxide, and Fenoldopam [3]. 2. **Mixed (Arterial + Venous) Dilators:** Sodium Nitroprusside (SNP), Alpha-blockers, and ACE inhibitors. 3. **Drug of Choice (DOC):** Hydralazine is the DOC for hypertension in pregnancy (though Labetalol is often preferred first-line now). 4. **Side Effect:** Pure arteriolar dilators often cause **reflex tachycardia** and fluid retention; therefore, they are frequently co-administered with Beta-blockers and diuretics [1], [3].

Question 1

Which antihypertensive drug is absolutely contraindicated in pregnancy?

Accepted Answer

Enalapril

Answer

Diazoxide

Answer

Atenolol

Answer

Nifedipine

Question 2

Captopril can cause all of the following except:

Accepted Answer

Decrease in K+ concentration

Answer

Decrease in afterload

Answer

Proteinuria

Answer

Blood dyscrasia

Question 3

Which of the following statements is NOT true about nesiritide?

Accepted Answer

It has significant oral absorption.

Answer

It is a brain natriuretic peptide analogue.

Answer

It is used in acutely decompensated heart failure.

Answer

It has a short half-life.

Question 4

Which of the following drugs can be used to treat hypertension induced by cyclosporine?

Accepted Answer

Enalapril

Answer

Clonidine

Answer

Nifedipine

Answer

Methyldopa

Question 5

Which of the following drugs or combination of drugs would be a suitable alternative to dobutamine for treating acute cardiac failure, providing a pharmacologic equivalent effect?

Accepted Answer

Norepinephrine plus phentolamine

Answer

Dopamine at a high dose

Answer

Ephedrine plus propranolol

Answer

Methoxamine plus atropine

Question 6

Iloprost in Pulmonary Arterial Hypertension is administered by which route?

Accepted Answer

Inhalation

Answer

Intravenous

Answer

Intramuscular

Answer

Oral

Question 7

What is the antihypertensive of choice for a hypertensive diabetic patient with proteinuria?

Accepted Answer

Enalaprilat

Answer

Propranolol

Answer

Clonidine

Answer

Alpha-methyldopa

Question 8

Renolazine is used in the management of which condition?

Accepted Answer

Angina

Answer

Hypertension

Answer

Tachycardia

Answer

Arrhythmia

Question 9

The antianginal effect of beta-blockers may be attributed to which one of the following?

Accepted Answer

Increase in diastolic perfusion time

Answer

Increased heart rate

Answer

Decreased end-diastolic ventricular volume

Answer

Increase in ejection time

Question 10

All of the following drugs cause arteriolar dilatation except?

Accepted Answer

Glyceryl trinitrate

Answer

Hydralazine

Answer

Diazoxide

Answer

Nifedipine

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?